<DOC>
	<DOCNO>NCT02635984</DOCNO>
	<brief_summary>The objective study compare effectiveness olanzapine add standard triplet therapy ( fosaprepitant , ondansetron , dexamethasone ) versus triplet therapy alone prevent chemotherapy-induced nausea vomiting ( CINV ) hematology patient receive highly moderately emetogenic chemotherapy regimen .</brief_summary>
	<brief_title>Study FOND Versus FOND+O Prevention CINV Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens</brief_title>
	<detailed_description>Nausea vomiting remain common difficult manage consequence chemotherapy despite prophylaxis . These symptom often lead decrease quality life , dehydration , malnutrition . Olanzapine atypical antipsychotic block multiple neuronal receptor involve nausea/vomiting pathway . Olanzapine study breakthrough chemo-induced nausea vomiting ( CINV ) well prophylaxis highly moderately emetogenic regimen ( HEC MEC , respectively ) . However , study focus patient solid tumor malignancy chemotherapy regimens short duration . To date , publication report outcome add olanzapine standard triplet therapy , hematology patient , include undergoing hematopoietic stem cell transplant receive multi-day HEC MEC regimens . This blind , placebo control trial randomizing patient receive olanzapine 10 mg orally chemotherapy day plus three additional day post chemotherapy placebo addition standard triplet therapy ( ondansetron dexamethasone day chemotherapy fosaprepitant 150 mg IV day one chemotherapy ) . Inclusion criterion : age 18 old , receive inpatient outpatient HEC MEC chemotherapy include regimen give stem cell transplantation ( ABVD , ICE ± R , 7+3 5+2 , BEAM , Bu/Cy ± ATG , Bu/Flu ± ATG , FluCy ± ATG , BuMel , FluBuCy , Melphalan ) . Exclusion criterion : allergy olanzapine , document nausea/vomiting ≤24 hour enrollment , treatment antipsychotic agent , decline informed consent . Patients randomize placebo olanzapine block design stratify chemotherapy type ( transplant conditioning vs. chemotherapy ) number day chemotherapy ( single vs. multi-day ) Investigational Drug Pharmacy service Augusta University Medical Center .</detailed_description>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Inpatient outpatient hematology patient receive one follow regimen : Chemotherapy hematologic malignancy : ABVD ICE ± R 7+3 Conditioning therapy stem cell transplantation : BEAM Bu/Cy ± ATG Bu/Flu ± ATG FluCy ± ATG FluCy + TBI BuMel FluBuCy Melphalan Etoposide + TBI Cyclophosphamide + TBI Allergy olanzapine Documented nausea vomit ≤24 hour prior enrollment Treatment antipsychotic agent risperidone , quetiapine , clozapine , phenothiazine butyrophenone ≤30 day prior enrollment plan protocol therapy Chronic alcoholism Pregnant Declined unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>